Skip to main content
IRS-authorized e-file provider · not the IRS

Nonprofit · EIN 87-4325698

HERPES CURE ADVOCACY

Tax-exempt · LOS ANGELES, CA 90049

Financials

$106K$46K2024
Revenue Expenses · by fiscal year end
Financials of HERPES CURE ADVOCACY by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2024990-EZ$105,751$45,841$59,910$75,360–$75,360
Financial details: 990-EZ for the year ended December 31, 2024

Revenue

Contributions, gifts and grants
$105,751

Expenses

Compensation of officers, directors and key employees
$0
Professional fees and payments to contractors
$27,393
Printing, publications and postage
$60
Other expenses
$18,388
Program services (functional)
$17,150

Balance sheet and other

Total assets, start of year
$15,450
Total assets, end of year
$75,360
Total liabilities, end of year
–
Net assets, end of year
$75,360
Cash, savings and investments
$75,360
Gross receipts
$105,751

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990-EZ for the year ended December 31, 2024, highest compensation first.

NameTitleHours / weekCompensation
DR JEFFREY KLAUSNERPRESIDENT6$0
DR GARY RICHWALDVICE PRESIDE6$0
NICOLE HANLEYSECRETARY6$0
KIMBERLY NEFFFOUNDER10$0
DR SIMON DELAGRAVEMEMBER4$0
CHARLES EBELMEMBER4$0
DR CHE HARRISMEMBER4$0
KARLAYNA KERNMEMBER6$0
DR LUIS SCHANGMEMBER4$0

Address and contacts

Address (IRS master file)
13001 SKY VALLEY RD, LOS ANGELES, CA 90049-1040
Mailing address (990-N for 2023)
13001 Sky Valley Road, Los Angeles CA 90049
Principal officer (990-N for 2023)
Jeffrey Klausner, 13001 Sky Valley Road, Los Angeles CA 90049
Signed the 990-EZ
DR JEFFREY KLAUSNER, PRESIDENT
Phone
(310) 396-2200
Return prepared by
ALLISON & GIBB LLP

California records

California keeps its own records of charities and corporations. Search them by EIN 87-4325698 or by the name HERPES CURE ADVOCACY.

Attorney General, Registry of Charities and Fundraisers
Registration status and filed reports (CT-TR-1, RRF-1)

Mission

INFORMED ADVOCACY RELATING TO THE CURE, TREATMENT AND PREVENTION FOR HERPES SIMPLEX VIRUS TYPES 1 + 2 INFECTIONS.

990-EZ for the year ended December 31, 2024

Program accomplishments

  • HERPES CURE ADVOCACY (HCA), FOUNDED IN MARCH 2022, IS A GRASS ROOTS, VOLUNTEER-DRIVEN NONPROFIT ORGANIZATION DEDICATED TO TACKLING ONE OF THE WORLD'S MOST PREVALENT BUT UNDER-ADDRESSED INFECTIONS CAUSED BY HERPES SIMPLEX VIRUS TYPES 1 AND 2 (HSV-1 & HSV-2). ESTABLISHED AS A 501(C)(3), THE ORGANIZATION ENVISIONS A FUTURE FREE FROM THE BURDEN OF HERPES, WHERE INFECTION, TRANSMISSION, STIGMA AND RELATED COMPLICATIONS ARE SIGNIFICANTLY REDUCED OR ELIMINATED ALTOGETHER. HCA'S MISSION IS TO SUPPORT THE CURE, TREATMENT, DIAGNOSIS, AND PREVENTION OF HERPES INFECTIONS. THE ORGANIZATION ACCOMPLISHES THIS THROUGH ACCELERATING RESEARCH, DRUG AND TEST DEVELOPMENT, EDUCATION, POLICY, AND GRASSROOTS ADVOCACY. HERPES CURE ADVOCACY HAS SUCCESSFULLY ELEVATED HERPES ONTO THE U.S. PUBLIC AND PERSONAL HEALTH CARE AGENDA BY HELPING DEVELOP AND PROMOTE A NATIONAL STRATEGY AND STRATEGIC PLAN FOR CURE, TREATMENT, AND PREVENTION OF HERPES. HCA'S ADVOCACY EFFORTS CATALYZED A JOINT CDC/NIH HERPES RESEARCH WORKSHOP IN 2022 AND THE CDC ISSUING REQUESTS FOR APPLICATIONS (RFAS) FOR IMPROVED HSV TESTING. IN 2023, THE NATIONAL INSTITUTES OF HEALTH (NIH) CONVENED A MULTI-COUNCIL WORKING GROUP ON HERPES, MARKING A NEW LEVEL OF INSTITUTIONAL COORDINATION. NIH RELEASED ITS STRATEGIC PLAN FOR HERPES SIMPLEX VIRUS (HSV) RESEARCH ON SEPTEMBER 19, 2023. THE PLAN, TITLED THE 2023-2028 NIH STRATEGIC PLAN FOR HERPES SIMPLEX VIRUS RESEARCH, IS LED BY THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID). ALONGSIDE THESE SUCCESSES, HCA HAS BUILT A GLOBAL GRASSROOTS MOVEMENT, MOBILIZED PATIENT, SCIENTIST AND POLICY MAKER VOICES, AND HELPED REDUCE STIGMA THROUGH EDUCATION AND COMMUNITY ENGAGEMENT. IN LATE 2024, THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) PUBLISHED THE FIRST AND GROUNDBREAKING HSV ADDENDUM TO THE SEXUALLY TRANSMITTED INFECTIONS (STI) NATIONAL STRATEGIC PLAN. THE ORGANIZATION'S WORK SPANS SEVERAL KEY AREAS. FIRST, HCA IS COMMITTED TO ADVANCING RESEARCH AND ACCELERATING THE DEVELOPMENT OF POTENTIAL CURES, PREVENTIVE MEASURES INCLUDING VACCINES, AND IMPROVED TESTING AND THERAPEUTICS. SINCE 2022 HCA HAS PUBLISHED TWO HERPES CURE PIPELINE RELEASES AND REPORTED ON PROMISING PRE-CLINICAL RESEARCH AND CLINICAL TRIALS FOR NEW THERAPIES TO TREAT HSV. BECAUSE THERE IS NO CURRENT CURE FOR HERPES AND EXISTING TREATMENTS ONLY PARTIALLY MANAGE SYMPTOMS AND REDUCE TRANSMISSION RISK, HCA PRIORITIZES EFFORTS THAT HELP PROMISING THERAPIES MOVE FROM THE LABORATORY INTO CLINICAL TRIALS. HCA ADVOCATES FOR THE DEVELOPMENT OF BETTER DIAGNOSTIC TOOLS. CURRENT TESTING TECHNOLOGIES CAN BE INACCURATE AND ARE UNDER RESEARCHED, WITH LIMITED DATA EXAMINING SCREENING BENEFITS, MAKING IT DIFFICULT FOR INDIVIDUALS TO KNOW THEIR INFECTION STATUS AND PREVENT TRANSMISSION. BY PUSHING FOR MORE RELIABLE AND ACCESSIBLE DIAGNOSTIC SOLUTIONS, HCA SEEKS TO CLOSE ONE OF THE BIGGEST GAPS IN THE PUBLIC AND PERSONAL HEALTH RESPONSE TO HERPES. POLICY AND ADVOCACY ARE ALSO CENTRAL PILLARS OF HCA'S MISSION. THE ORGANIZATION ENGAGES WITH LAWMAKERS, PUBLIC HEALTH OFFICIALS, RESEARCHERS AND REGULATORY AGENCIES TO ELEVATE HERPES ON THE PUBLIC AND PERSONAL HEALTH AGENDA, ADDRESSES FUNDING PRIORITIES, AND PROMOTES COORDINATED NATIONAL STRATEGIES. THESE ADVOCACY EFFORTS ARE REINFORCED BY AN EQUALLY IMPORTANT FOCUS ON EDUCATION AND IMPROVING CLINICAL CARE. TO THIS END, HCA OPERATES MONTHLY EDUCATIONAL PROGRAMS FOR PATIENTS AND PROFESSIONALS. IN 2024 AND 2025, HCA PARTNERED WITH THE HIV VACCINE TRIALS NETWORK (HVTN) ORGANIZATION TO LEAD A SERIES OF SCIENTIFIC TALKS ON HSV FOR A NATIONAL AUDIENCE. THE IMPORTANCE OF HCA'S WORK CANNOT BE OVERSTATED. HERPES IS HIGHLY PREVALENT WORLDWIDE, YET ITS BURDEN IS OFTEN UNDERESTIMATED BECAUSE MANY INFECTIONS ARE ASYMPTOMATIC OR MISDIAGNOSED. BEYOND PAINFUL OUTBREAKS, HERPES CAN LEAD TO SEVERE COMPLICATIONS SUCH AS NEONATAL HERPES, ENCEPHALITIS, OR INCREASED VULNERABILITY TO OTHER IMPORTANT HEALTH CONDITIONS. RESEARCH HAS ALSO IDENTIFIED POTENTIAL ASSOCIATIONS BETWEEN HSV AND LONG-TERM NEUROLOGICAL DISORDERS SUCH AS ALZHEIMER'S DISEASE. ON TOP OF THE PHYSICAL TOLL, THE PSYCHOLOGICAL AND EMOTIONAL BURDEN OF HERPES IS IMMENSE. THE INFECTION IS OFTEN ACCOMPANIED BY STIGMA, SHAME, AND SOCIAL ISOLATION, WHICH CAN DEEPLY IMPACT MENTAL AND SEXUAL HEALTH. BY ADDRESSING BOTH THE BIOMEDICAL AND SOCIAL DIMENSIONS OF HERPES, HCA IS WORKING TOWARD A FUTURE THAT PRIORITIZES HOLISTIC WELL-BEING FOR THOSE AFFECTED AND ENSURES THAT THE MILLIONS AFFECTED BY HERPES HAVE A VOICE, A COMMUNITY, AND A PATH FORWARD. THE CURRENT HERPES CURE ADVOCACY BOARD OF DIRECTORS IS COMPOSED OF EXPERTS AND ADVOCATES SPANNING MEDICINE, PUBLIC HEALTH, VIROLOGY, BEHAVIORAL SCIENCES, LAW, BUSINESS DEVELOPMENT, COMMUNITY EMPOWERMENT, AND PATIENT ADVOCACY. DR. JEFFREY KLAUSNER SERVES AS PRESIDENT AND BRINGS DEEP EXPERIENCE IN STI EPIDEMIOLOGY AND APPLIED PUBLIC HEALTH. DR. GARY RICHWALD IS VICE PRESIDENT AND A COMMUNICABLE DISEASE AND HEALTH SERVICES RESEARCH EXPERT AND HAS SERVED AS DIRECTOR OF ONE OF THE LARGEST STI PROGRAMS IN THE USA. DR. LAO-TZU ALLAN-BLITZ ACTS AS SECRETARY, CONTRIBUTING EXPERTISE IN INFECTIOUS DISEASE DIAGNOSTICS AND GLOBAL HEALTH EQUITY. MS. NICOLE HANLEY IS TREASURER AND COMBINES PSYCHIATRIC AND FAMILY NURSE PRACTITIONER ROLES WITH PARTICULAR INTEREST IN THE MENTAL HEALTH AND COMMUNITY DIMENSIONS OF HSV. THE "AT LARGE" BOARD MEMBERS INCLUDE DR. LUIS SCHANG, MOLECULAR VIROLOGIST FOCUSED ON ANTIVIRAL DISCOVERY; MS. KARLAYNA KERN, PATIENT ADVOCATE WHO HANDLES COMMUNICATIONS AND COMMUNITY ENGAGEMENT; DR. KENNETH LAWRENCE, INFECTIOUS DISEASE PHARMACOLOGY/MEDICAL AFFAIRS LEADER; MS. AMY FINK, ATTORNEY, MS. DEB LEVINE, NONPROFIT FOUNDER AND DIRECTOR, AND MS. REINA SAMARO, SAFETY DIRECTOR AND HERPES PATIENT ADVOCATE.
    Expenses $17,150

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026Not on file
2024December 31, 2024May 15, 2025990-EZ on file
2023December 31, 2023May 15, 2024990-N on file

File the 2025 990-EZ for HERPES CURE ADVOCACY

Due May 15, 2026 · e-filed with the IRS by 990.tax, an IRS-authorized e-file provider

IRS record

EIN
87-4325698
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (170(b)(1)(A)(vi))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
2022
Accounting year ends
December
Files
Form 990 or 990-EZ
Assets (IRS master file)
$75,360
Income (IRS master file)
$105,751

Filing history

FormYear endedRevenueExpensesAssetsReturn
990-EZDecember 2024$105,751$45,841$75,360XML
990-N for 2023
Officer: Jeffrey Klausner
December 31, 2023≤ $50,000 receipts––e-Postcard
990-N for 2022
Officer: Jeffrey Klausner
December 31, 2022≤ $50,000 receipts––e-Postcard

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 87-4325698).

Questions about HERPES CURE ADVOCACY

What is the EIN of HERPES CURE ADVOCACY?
The employer identification number (EIN) of HERPES CURE ADVOCACY is 87-4325698.
Is HERPES CURE ADVOCACY tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2022.
Are donations to HERPES CURE ADVOCACY tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does HERPES CURE ADVOCACY file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of HERPES CURE ADVOCACY due?
The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
When did HERPES CURE ADVOCACY last file with the IRS?
The latest return in the IRS public files is the 990-EZ for the year ended December 2024.
Who is the principal officer of HERPES CURE ADVOCACY?
The 990-N for 2023 names Jeffrey Klausner.
Who are the officers and directors of HERPES CURE ADVOCACY?
The 990-EZ for the year ended December 31, 2024 lists 9 people; 0 received compensation from the organization.
How much revenue does HERPES CURE ADVOCACY have?
On its 990-EZ for the year ended December 31, 2024 it reported revenue of $105,751, expenses of $45,841 and total assets of $75,360 at year end.

Other nonprofits in LOS ANGELES

All nonprofits in LOS ANGELES · California · Voluntary health associations and medical disciplines